Navigation Links
Islet Sciences, Inc. Technologies Featured in Five Separate Presentations at the American Diabetes Association Annual Meeting
Date:6/24/2013

NEW YORK, June 24, 2013 /PRNewswire/ -- Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announces that its technologies were featured at the American Diabetes Association annual meeting.

The presentations were made in part by members of Islet's Scientific Advisory Board, which included Dr. Jonathan Lakey, Dr. Kevan Harold and Dr. Eitan Akirav.   Sessions presented by Islet highlighted the following: 1) Circulating demethylated insulin as a potential early indicator of beta cell loss, 2) Immune therapy and type one diabetes previously discussed in the ADA journal 'Diabetes,' 3) New inhibitors to preserve and protect islet function, 4) Prolonged Euglycemia following transplantation of alginate encapsulated porcine islet cells, and 5) Consistency and scalability of young porcine islet isolation.

"We are excited to see that our technologies were accepted for presentation at the American Diabetes Association's annual meeting," said John Steel, Chairman and Chief Executive Officer of Islet Sciences. "This clearly provides further evidence for the value and promise for these technologies to be developed for treatments for diabetes and related complications."

"The technologies we have developed are groundbreaking and the recognition we continue to see from such well respected organizations such as the American Diabetes Association is extremely validating," stated Dr. Jonathan Lakey, Chief Scientific Officer and Chairman of the Scientific Advisory Board of Islet Sciences. The presentation of these technologies are another aspect to the value of our therapies which represents such a large market opportunity for the Diabetic community."

The technologies presented at the ADA meeting have received grant support from Department of Defense, National Institute of Health, Juvenile Diabetes Research Foundation, as well as funding from Islet Sciences. 

About Islet Sciences, Inc.


Islet Sciences is a development-stage biotechnology company with patented technologies focused on infusion therapy for people with insulin-dependent diabetes.  The Company's infusion technology includes methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells. The Company's mission includes the introduction of commercial products relevant to the insulin dependent diabetes marketplace including diagnostics and anti-inflammatory compounds. For more information: www.isletsciences.com

Forward-Looking Statements


This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements for Islet Sciences reflect current expectations, as of the date of this press release, and involve certain risks and uncertainties.   Actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors.  Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the risks described in the Islet Science's reports filed with the Securities and Exchange Commission.  The companies' further development is highly dependent on future medical and research developments and market acceptance, which is outside their control.

Investor Contact:
Jeff Ramson

ProActive Capital Group
646-863-6341
jramson@proactivecapital.com

Media Contact:
Sandra Lee
ProActive Capital Group
646-863-6341
slee@proactivecapital.com


'/>"/>
SOURCE Islet Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Islet Sciences Announces Exclusive License Agreement with the University of California (UCLA) to Commercialize Small Molecules for Islet Expansion
2. Islet Sciences Announces Exclusive License Agreement with Winthrop University Hospital to Commercialize a Beta Cell Loss Measurement Technology in Diabetes
3. Islet Sciences Names Richard A. Franco, Sr. to its Board of Directors
4. Islet Sciences Announces Receipt of $2.1 Million in Grant Support of Technology
5. Islet Sciences Announces DiaKine Therapeutics Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection
6. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
7. Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal
8. Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update
9. MedeAnalytics Ken Perez Predicts Rapid Growth of Healthcare Data Analytics Market at Conference on Data Analytics in Life Sciences, Healthcare and Biotech Companies
10. Regado Biosciences, Inc. Files Registration Statement for Proposed Initial Public Offering
11. VG Life Sciences, Inc. Secures Two-Year Funding Commitment and Administrative Support from MedBridge, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)...  Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing ... that Linda Marbán, Ph.D, president and chief executive officer, is ... Cowen and Company 37th Annual Health Care Conference ... Boston, MA 29th Annual ROTH ... pm ET) Dana Point, CA ...
(Date:2/23/2017)... CARDIFF, UK (PRWEB) , ... February 22, 2017 ... ... for optics and photonics , have been named Fellows of the Society this ... and technical contributions in the multidisciplinary fields of optics, photonics, and imaging as ...
(Date:2/22/2017)... ... February 22, 2017 , ... Park Systems , ... AFM Luncheon for all SPIE attendees and Park customers on Feb. ... block from the San Jose Convention Center. The luncheon will feature a talk ...
(Date:2/22/2017)... Washington, PA (PRWEB) , ... ... ... Omnia-Prova Education Collaborative (TOPEC), the leading medical education provider of women’s ... with Commendation by the Accreditation Council for Continuing Medical Education (ACCME). ACCME’s ...
Breaking Biology Technology:
(Date:2/13/2017)... 2017 Former 9/11 Commission border counsel and ... Janice Kephart of Identity Strategy Partners, LLP, today ... "Executive Order: Protecting the Nation From Foreign Terrorist ... "As President Trump,s ,Travel Ban, Executive Order gains ... banned the travel ban, it is important that our ...
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
(Date:2/7/2017)... , Feb. 7, 2017   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... , its innovative, highly flexible and award winning eClinical ... customers. iMedNet is a proven Software-as-a-Service (SaaS) ... Data Capture (EDC), but also delivers an entire suite ...
Breaking Biology News(10 mins):